Select your timezone:

Ryo Ito, Japan

Head, Chief Manufacturing & Technology Officer
iPSC-derived Pancreatic Islet Cell Business Unit
Orizuru Therapeutics, Inc.

Chief Manufacturing & Technology Officer 2022- Orizuru Therapeutics, Inc. Business Head 2021- iPSC-derived Pancreatic Islet Cell (iPIC) Therapy, Orizuru Therapeutics, Inc. - One of the founding members of biotech venture, Orizuru - Currently responsible for developing business plan of iPIC therapy Associate director 2015-2021 T-CiRA* joint program, Takeda Pharmaceutical Company Limited - Led iPIC research as a co-principal investigator of Takeda in collaboration with Dr. Toyoda, a principal investigator of CiRA - Acquired 2.7 oku yen public funding (AMED) based on the research results * Takeda and CiRA, Center for iPS Cell Research and Application, Kyoto University Principal Scientist 2011-2015 Cardiovascular and Metabolic Drug Discovery Unit, Takeda Pharmaceutical Company Limited - >10-year of research experience in diabetes fields - Involved in drug discovery research to New Drug Application of several anti-diabetes drugs including NESINA Scientist 2004-2011 Takeda Pharmaceutical Company Limited

Organized by

A section of

© 2024 BetaCells 2023